SCHEMBL1770199

SCHEMBL1770199

CNc1ccc(C(=O)C2CCCc3nc(NC(C)=O)sc3C2=O)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
TP53 P04637 2/20 0.39
POLB P06746 1/20 0.39
HCAR3 P49019 1/20 0.38
NNMT P40261 1/20 0.37
LMNA P02545 3/20 0.37
HPGD P15428 3/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
PIK3CG P48736 6/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
GFER P55789 2/20 0.33
PI4KB Q9UBF8 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694720 0.91 NPC1 (0.38) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL1770530 0.90 HCAR3 (0.41) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL1770594 0.88 PIK3CG (0.40) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL1770620 0.87 NPC1 (0.38) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL12598927 0.87 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL1770505 0.87 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL1770625 0.86 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL12598910 0.86 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL1770791 0.85 PARP1 (0.35) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL691532 0.85 NNMT (0.41) ALDH1A1NPC1RAB9AHCAR3NNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421871-B1 THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2015-09-16 EP disclosed
EP-2421871-B1 THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2015-09-16 EP disclosed
US-8288379-B2 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-16 US disclosed
US-8288379-B2 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-16 US disclosed
US-8288379-B2 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-16 US disclosed
US-20110112087-A1 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-12 US disclosed
US-20110112087-A1 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-12 US disclosed
US-20110112087-A1 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-12 US disclosed
WO-2010122071-A1 THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112087-A1 Thia-triaza-cyclopentazulenes CCNA1, MKI67, CCNT1 ALDH1A1 147/4885SMN1; SMN2 780/4885NPC1 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.